Contribute Try STAT+ Today

Another key patent on the CRISPR genome editing technology is facing a legal challenge. On Tuesday, St. Louis-based Benson Hill Biosystems, a privately held agriculture biotech company, filed a petition for post-grant review with the U.S. Patent and Trademark Office, arguing that a CRISPR patent granted to the Broad Institute of MIT and Harvard in 2017 and licensed by Editas Medicine (EDIT) is invalid.

The challenged patent (number 9,790,490) covers CRISPR systems that use not the original Cas9 enzyme but a family of enzymes that the Broad’s Feng Zhang and his colleagues discovered in 2015. Originally called Cpf1 and now known as Cas12a, this family of enzymes cleave DNA at a target site, as Cas9 does. But Cpf1 has several advantages over the original, including working at regions of the genome that are inaccessible to Cas9 and being able to cut DNA without the addition of a molecule called tracrRNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.